Benzinga | Apr 14, 2021 07:36AM EDT

Moleculin Awarded New Rare Pediatric Disease Designation From US FDA For WP1066 For The Treatment Of Ependymoma

Moleculin Biotech, Inc., (NASDAQ:MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, announced today that the U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation (RPD) to its p-STAT3 inhibitor, WP1066, for the treatment of ependymoma.